TY - JOUR
T1 - Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography
AU - Floresta, Giuseppe
AU - Abbate, Vincenzo
N1 - Funding Information:
The authors gratefully acknowledge Professor Phil Blower (Professor of Imaging Chemistry and Head of Department of Imaging Chemistry and Biology, King's College London) for helpful discussions during the manuscript drafting process. This project has received funding from the European Union's Horizon 2020 Research and Innovation Program under Grant agreement no 893784.
Publisher Copyright:
© 2022 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.
PY - 2022/3/16
Y1 - 2022/3/16
N2 - Tyrosine-protein kinase Met—also known as c-Met or HGFR—is a membrane receptor protein with associated tyrosine kinase activity physiologically stimulated by its natural ligand, the hepatocyte growth factor (HGF), and is involved in different ways in cancer progression and tumourigenesis. Targeting c-Met with pharmaceuticals has been preclinically proved to have significant benefits for cancer treatment. Recently, evaluating the protein status during and before c-Met targeted therapy has been shown of relevant importance by different studies, demonstrating that there is a correlation between the status (e.g., aberrant activation and overexpression) of the HGFR with therapy response and clinical prognosis. Currently, clinical imaging based on positron emission tomography (PET) appears as one of the most promising tools for the in vivo real-time scanning of irregular alterations of the tyrosine-protein kinase Met and for the diagnosis of c-Met related cancers. In this study, we review the recent progress in the imaging of c-Met aberrant cancers with PET. Particular attention is directed on the development of PET probes with a range of different sizes (HGF, antibodies, anticalines, peptides, and small molecules), and radiolabeled with different radionuclides. The goal of this review is to report all the preclinical imaging studies based on PET imaging reported until now for in vivo diagnosis of c-Met in oncology to support the design of novel and more effective PET probes for in vivo evaluation of c-Met.
AB - Tyrosine-protein kinase Met—also known as c-Met or HGFR—is a membrane receptor protein with associated tyrosine kinase activity physiologically stimulated by its natural ligand, the hepatocyte growth factor (HGF), and is involved in different ways in cancer progression and tumourigenesis. Targeting c-Met with pharmaceuticals has been preclinically proved to have significant benefits for cancer treatment. Recently, evaluating the protein status during and before c-Met targeted therapy has been shown of relevant importance by different studies, demonstrating that there is a correlation between the status (e.g., aberrant activation and overexpression) of the HGFR with therapy response and clinical prognosis. Currently, clinical imaging based on positron emission tomography (PET) appears as one of the most promising tools for the in vivo real-time scanning of irregular alterations of the tyrosine-protein kinase Met and for the diagnosis of c-Met related cancers. In this study, we review the recent progress in the imaging of c-Met aberrant cancers with PET. Particular attention is directed on the development of PET probes with a range of different sizes (HGF, antibodies, anticalines, peptides, and small molecules), and radiolabeled with different radionuclides. The goal of this review is to report all the preclinical imaging studies based on PET imaging reported until now for in vivo diagnosis of c-Met in oncology to support the design of novel and more effective PET probes for in vivo evaluation of c-Met.
UR - http://www.scopus.com/inward/record.url?scp=85126275464&partnerID=8YFLogxK
U2 - 10.1002/med.21885
DO - 10.1002/med.21885
M3 - Article
SN - 0198-6325
VL - 42
SP - 1588
EP - 1606
JO - Medicinal Research Reviews
JF - Medicinal Research Reviews
IS - 4
ER -
